1-6 of 6
Kallesh D. Jayappa
Close
Sort by
Journal Articles

Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, Luke R. Vass, Caroline Farrington, Anuradha Illendula, Susan Walker, Michael E. Williams, Craig A. Portell, Todd Fox, Goutham Narla, Mark Kester
Journal: Blood
Blood (2022) 140 (Supplement 1): 7816–7817.
https://doi.org/10.1182/blood-2022-168086
Published: 2022
Journal Articles

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, PhD, Caroline Farrington, PhD, Vicki L. Gordon, BS, Shekhar Saha, PhD, Christopher Morris, BS, Krista M. Isaac, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Goutham Narla, MD PhD, Michael J. Weber, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-138954
Published: 2020
Journal Articles

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Konrad J. Cios, BSc (2019), Vicki L. Gordon, BSc, Puja C. Arora, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Michael J. Weber, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4120.
https://doi.org/10.1182/blood-2018-99-119521
Published: 2018
Journal Articles

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L. Gordon, BSc, Goutham Narla, MD PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2649.
https://doi.org/10.1182/blood-2018-99-116759
Published: 2018
Journal Articles

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L Gordon, BS, Brian J Capaldo, PhD, Stefan Bekiranov, PhD, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD
Journal: Blood
Blood (2016) 128 (22): 754.
https://doi.org/10.1182/blood.V128.22.754.754
Published: 2016
Journal Articles

Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199)

Kallesh D. Jayappa, PhD, Craig A. Portell, MD, Vicki Gordon, B.S., Michael E. Williams, MD, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael J. Weber, PhD
Journal: Blood
Blood (2015) 126 (23): 448.
https://doi.org/10.1182/blood.V126.23.448.448
Published: 2015